Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US & Australia

    A Phase 2 Study to evaluate efficacy and safety of VX-561 in adults 18 years and older with cystic fibrosis , protocol number NCT03911713 VERTEX VX-561-101

    This study will look at the safety and effectiveness of the drug VX-561, a drug intended to help CFTR function closer to normal. This study is randomized and placebo-controlled. This means that some participants will receive one of four dose levels of the study drug, some participants will receive ivacaftor, and some participants will receive placebo. In this study, researchers will test the effectiveness of VX-561 by monitoring lung function. They will also monitor sweat chloride and adverse events. This study may require lung function tests, blood samples, and/or other measures.

    • Age:

      18 years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      40 to 100%

    • Number of Visits:

      8

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation , protocol number NCT02730208 VX15-661-112

    A Phase 2, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    • Age:

      >12 years

    • Mutation(s):

      Homozygous for the F508del CFTR mutation

    • FEV1% Predicted:

      ppFEV1 ≥70% of predicted normal

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US & NSW, Australia

    Study of VX-445 triple combination in children 6-11 years old with cystic fibrosis , protocol number NCT03691779 VX18-445-106

    This study evaluated the safety and effectiveness of the triple combination modulator therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®) in children ages 6-11 years with CF who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.

    • Age:

      6 Years to 11 Years

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      9

    • Length of Participation:

      32

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US & Australia

    Phase 1/2 Study of VX-445 combination drug in healthy adults and then in people with cystic fibrosis. , protocol number NCT03227471 VX16-445-001

    This study is taking place at multiple care centres across the US and Australia. It will look at the safety and effectiveness of the drug VX-445.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      6

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Australia

    A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation , protocol number NCT02875366 VX15-809-112

    A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

    • Age:

      >12 years

    • Mutation(s):

      Homozygous F508del

    • FEV1% Predicted:

      FEV1 at least 40% and not greater than 90% of predicted.

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherActive, not recruiting Location: Australia, Melbourne

    CPET in CF patients with one G551D mutation taking VX770 , protocol number NCT01937325

    Double-blind, placebo-controlled cross-over study of 20 patients currently awaiting initiation of ivacaftor therapy.

    • Age:

      16-70 years

    • Mutation(s):

      Hetrozygous G551D

    • FEV1% Predicted:

      > 25%

    • Number of Visits:

      Not specified

    • Length of Participation:

      224 days

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Australia, Melbourne

    The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function , protocol number NCT00164021 NCT00164021

    A factorial longitudinal study will be undertaken in adults with cystic fibrosis. Results will be compared with age matched healthy controls. It is not deemed appropriate to randomise patients with gastro-oesophageal reflux(GOR) to a treatment versus no treatment group as immediate treatment for GOR once diagnosed is regarded as obligatory. Subjects: 180 adults with CF will be recruited from the Adult Cystic Fibrosis Unit at the Alfred Hospital to participate in the study. The ambulatory studies will be undertaken during baseline state in the outpatient setting. Fifteen age matched control subjects will be recruited from the general population.

    • Age:

      16-70 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia - VIC

    The Alfred Step Test Exercise Protocols (A-STEP and A-STEPmax): Developed for Adults With Cystic Fibrosis (A-STEP/max) , protocol number NCT02717650

    Feasibility and Validation of the Alfred Step Test Exercise Protocols (A-STEP and A-STEPmax): Developed to Assess Exercise Tolerance and Determine Maximum Oxygen Uptake in Adults With Cystic Fibrosis Across the Disease Spectrum

    • Age:

      >18 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      FEV1 greater than 20%

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation , protocol number NCT02742519 VX15-770-123

    A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long-term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

    • Age:

      3-5 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: LOCATION: Perth Linear Clinical Research, Contact: Jennifer Seabourne CONTACT: [email protected] Brisbane-Q-pharm CONTACT: Sharon Rankine Phone: 0439 664 900,; Email: [email protected]

    A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants , protocol number NCT03173573 FDL176-2016-01

    This is a 5-part study. Part 1 is a double blind, placebo-controlled, dose escalation, first-in-human study to assess the safety, tolerability and PK profiles following single oral administration of FDL176 to healthy male participants. Part 2 is a single dose, open-label study in healthy male participants to determine the effect of food on the PK profile of FDL176. Part 3 is a single dose, double blind, placebo-controlled study in healthy female participants to assess the PK, safety and tolerability profiles of FDL176. Part 4 is a randomised, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability and PK profiles following multiple oral administrations of FDL176 to healthy male and female participants. Part 5 is a single dose, open-label study in male and female participants with CF to determine the PK profile of FDL176.

    • Age:

      18 Years to 55 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Displaying results 81-90 (of 200)
     |<  <  5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14  >  >|